Rate My Professor Arindam Pramanik

Dr. Arindam Pramanik serves as Assistant Professor (II) at the Amity Institute of Biotechnology, Amity University, Noida, a role he assumed on December 19, 2022. Previously, he was a Postdoctoral Fellow in the Faculty of Biological Sciences at the University of Leeds, United Kingdom, from January 1, 2017, to November 30, 2022, including a Newton International Fellowship from 2017 to 2018. His educational background includes a Ph.D. in Biotechnology from Jadavpur University in 2016, an M.Sc. in Microbiology from the University of Kalyani in 2010, and a B.Sc. (MCZ) from St. Joseph’s Autonomous College, Bangalore, in 2008. He qualified the GATE examination in 2011.

Dr. Pramanik has been honored as an INSA Visiting Scientist at IIT Delhi. He leads the Applied Nano & Biomaterials Laboratory, specializing in the design and translational development of advanced biomaterial-based therapeutics addressing unmet clinical needs. His research interests encompass lipid nanocarriers for targeted delivery of combinatorial therapeutics—such as siRNA, small-molecule inhibitors, and chemotherapeutics—to combat drug resistance in cancer treatment. The laboratory also develops nanoengineered hydrogel systems for diabetic wound healing, facilitating controlled drug release and tissue regeneration. Funding supports include grants from the Indian Council of Medical Research (Small Extra-mural Grant and Intermediate Grant) and the Anusandhan National Research Foundation (Prime Minister Early Career Research Grant). Notable publications feature “Design and Synthesis of Peptide-Tagged Cubosome Nanocarriers for the Targeted Delivery of Paclitaxel in EGFR Overexpressing Breast Cancer” (ACS Biomaterials Science & Engineering, 2026), “EGFR-Targeted and MMP-Activated Membranolytic Peptides Kill Cancer Cells Specifically In Vitro and Reduce Tumor Growth In Vivo” (Molecular Pharmaceutics, 2026), “Affimer Tagged Cubosomes: Targeting of Epidermal Growth Factor Receptor Overexpressing Breast Cancer Cells” (Advanced Therapeutics, 2022), and “Designing Stimuli-Responsive Upconversion Nanoparticles for Immunomodulation and Cancer Therapy” (Advanced Materials, 2020). He holds the position of Associate Editor for Biomedical Nanotechnology in Frontiers in Nanotechnology.